Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13 USD | -1.14% | -3.85% | +51.16% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 645M |
---|---|---|---|---|---|
Net income 2024 * | -142M | Net income 2025 * | -173M | EV / Sales 2024 * | - |
Net cash position 2024 * | 105M | Net cash position 2025 * | 137M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-4.34
x | P/E ratio 2025 * |
-4.06
x | Employees | 28 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.47% |
Latest transcript on Mineralys Therapeutics, Inc.
1 day | -1.14% | ||
1 week | -3.85% | ||
Current month | +6.12% | ||
1 month | +20.93% | ||
3 months | -16.02% | ||
6 months | +90.34% | ||
Current year | +51.16% |
Managers | Title | Age | Since |
---|---|---|---|
Jon Congleton
CEO | Chief Executive Officer | 60 | 20-10-31 |
Adam Levy
DFI | Director of Finance/CFO | 46 | 22-02-28 |
Jessica Ibbitson
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 56 | 21-01-31 | |
Glenn Sblendorio
BRD | Director/Board Member | 68 | 23-09-12 |
Director/Board Member | 58 | 21-01-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +3.87% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 13 | -1.14% | 45,212 |
24-05-16 | 13.15 | +0.61% | 57,845 |
24-05-15 | 13.07 | +0.08% | 75,448 |
24-05-14 | 13.06 | +1.01% | 74,411 |
24-05-13 | 12.93 | -4.36% | 127,537 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+51.16% | 645M | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B | |
-6.26% | 11.42B |
- Stock Market
- Equities
- MLYS Stock